2020 American Transplant Congress
The Impact of HLA-DQ Molecular Mismatches on De Novo Occurrence of Donor-Specific Anti-HLA Antibodies after Kidney Transplantation: An Observational Cohort Study
*Purpose: Evaluating HLA molecular mismatches (MM) instead of antigen mismatches might be a better tool to assess donor-recipient HLA incompatibility and provide a better risk…2020 American Transplant Congress
Low HLA Class I Epitope Mismatch Associated with Improved Pancreas Graft Survival in Simultaneous Pancreas-Kidney Transplantation
University of Alabama-Birmingham, Birmingham, AL
*Purpose: Antibody-mediated rejection remains the principal cause of allotransplant graft failure. Human leukocyte antigen (HLA) matching between donor and recipients significantly reduces the risk of…2020 American Transplant Congress
Calculated Panel Reactive Antibody Values Increase for Kidney Transplant Candidates with HLA-DQA and HLA-DPB Unacceptable Antigens
*Purpose: Calculated panel-reactive antibody (CPRA) is the official metric of sensitization used by the United Network for Organ Sharing (UNOS) for kidney allocation. CPRA includes…2020 American Transplant Congress
HLA Diversity Affects Epitope Mismatch Cutoffs Utilized to Predict De Novo DSA Development and Graft Rejection in Renal Transplant Patients
*Purpose: Recent studies have investigated epitope matching in order to determine its predictive power in determining renal transplant outcomes, both in terms of de novo…2020 American Transplant Congress
HLA Specific Antibody Levels after EDTA Treatment in CDC Crossmatch Positive and Negative Sera with Known Donor-Specific Antibodies
*Purpose: Ethylenediaminetetraacetic acid (EDTA) treatment of serum samples overcomes the prozone effect that may interfere with solid phase HLA specific antibody analyses. In patients with…2020 American Transplant Congress
MHC II-Decoy Car-T Cells to Induce Long-Term Allotransplant Organ Tolerance
*Purpose: Allotransplantation represents the definitive therapy for end-stage renal, heart, liver, and lung disease. Current immunosuppressive regimens fail to promote long-term engraftment, leading to chronic…2020 American Transplant Congress
Attempted Validation of Lims1 Variant Rs893403 with Acute Rejection Risk
1University of Minnesota, Minneapolis, MN, 2University of Alabama, Birmingham, AL
*Purpose: Acute rejection (AR) in kidney allograft recipients is a significant risk factor for reduced graft survival. Identifying individuals at risk for AR could facilitate…2019 American Transplant Congress
Emergence of Anti-HLA Antibodies after Catch-Up Vaccinations in Pediatric Kidney Transplant Candidates
*Purpose: Evaluate anti-HLA antibody (Ab) emergence after catch-up vaccinations in pediatric kidney transplant candidates (PKTC).*Methods: A single center retrospective review of PKTC 25% from baseline,…2019 American Transplant Congress
Predicted Indirectly Recognizable H L A Epitopes Are Associated with T-cell Mediated Rejection among Kidney Transplant Recipients with Preformed and De Novo Donor-Reactive T-cells
*Purpose: Very recently Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) have been suggested to demonstrate early and late effects on kidney allograft outcomes. The association between…2019 American Transplant Congress
Non-HLA Antibodies against Structural and Non-Structural Target in C4d Negative Antibody Mediated Rejections after Renal Transplantation
*Purpose: According to the latest Banff’s criteria approved in 2003, antibody mediated rejections following renal transplantation are divided into 2 types namely C4d + and…
American Transplant Congress abstracts